Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") is the first company in China and the second globally to commercialize both multi-port and single-port surgical robots, officially listing on the Hong Kong Stock Exchange on January 8, 2026 [1] Group 1: IPO and Financial Performance - Precision Medical issued a total of 27,722,200 H-shares in its IPO, with a subscription rate of 1,091.94 times for the Hong Kong public offering and 25.18 times for the international offering [3] - The company raised approximately HKD 1.199 billion at an issue price of HKD 43.24 per share, with an opening price of HKD 59, resulting in a market capitalization exceeding HKD 22.8 billion [3] - In the first half of 2025, Precision Medical achieved revenue of approximately RMB 149 million, representing a nearly 400% year-on-year growth, with a gross margin of about 62.8% [3] Group 2: Future Plans and Innovations - Precision Medical aims to leverage its IPO as a new starting point to increase investment in cutting-edge technologies, complex surgical procedures, and remote surgery, while steadily advancing capacity building and global market expansion [3] - The company is committed to providing safer, more efficient, and affordable minimally invasive surgical solutions, contributing to the high-quality development of China's high-end medical equipment industry [4] Group 3: Company Background and Technology - Founded in May 2017, Precision Medical is a strategic investment enterprise of the National Social Security Fund and a key player in the field of domestically developed surgical robots in China [6] - The company has developed a comprehensive product portfolio, including multi-port and single-port surgical robots, bronchoscopic surgical robots, and traditional minimally invasive surgical instruments, supported by a robust R&D team and a strong intellectual property foundation with 734 patents [6] - Precision Medical has established a "three-in-one" surgical solution combining multi-port, single-port, and remote systems, promoting advancements in surgical techniques and sharing high-quality medical resources globally [6]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., has shown significant growth in its stock performance and is benefiting from various market trends, including the pet economy and medical device sector, as well as the depreciation of the RMB [1][2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on ultrasound technology [2][3]. - The company was established on November 15, 1982, and went public on January 22, 2025 [7]. - The main revenue sources for the company are medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [7][8]. - As of September 30, 2025, the company had a total market capitalization of 10.151 billion yuan [1]. Market Position and Trends - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. - The stock has experienced a recent increase of 5.15% in value, with a trading volume of 166 million yuan and a turnover rate of 12.02% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which is a decrease of 388,200 shares compared to the previous period [9].

Core Viewpoint - Venezuela has agreed to use its oil sales revenue exclusively for purchasing American-made goods, including agricultural products, pharmaceuticals, medical equipment, and equipment for improving its electrical grid and energy facilities [1] Group 1 - The announcement was made by U.S. President Trump on January 7 via his social media platform "Truth Social" [1] - As of the time of reporting, there has been no response from the Venezuelan side regarding this agreement [1]

Core Insights - The medical device ETF (159873) has seen a significant increase in trading volume and share growth, with a turnover of 4.65% and a transaction value of 5.525 million yuan as of January 8, 2026, reflecting a strong performance in the sector [1] - The underlying index, the CSI All Share Medical Devices and Services Index (H30178), rose by 1.83%, with notable gains from individual stocks such as Kefu Medical (301087) up 19.78%, Shuoshi Biology (688399) up 11.51%, and Lepu Medical (300003) up 7.99% [1] - Over the past two weeks, the medical device ETF has grown by 8.6124 million yuan in scale and 8 million shares in volume, indicating robust investor interest [1] Product Highlights - The medical device ETF (159873) closely tracks the CSI All Share Medical Devices and Services Index, which selects listed companies in the healthcare sector to reflect the overall performance of the theme [1] Hot Events 1. Eight departments, including the Ministry of Industry and Information Technology, have issued an implementation opinion to accelerate the industrialization and commercialization of new terminals such as brain-computer interfaces, aiming for significant advancements in AI technology by 2027 [2] 2. Sichuan Province has set a maximum price of 6,583 yuan per session for brain-computer interface medical services, effective from April 30 this year, as part of a broader integration of 82 neurological service pricing projects [2] Institutional Views - The brain-computer interface industry is entering a phase of accelerated industrialization, supported by a comprehensive policy framework that includes planning, payment, and standards [2] - Zhongyin Securities notes that the National Medical Insurance Administration established independent charging items for invasive and non-invasive brain-computer interfaces in March 2025, with further support from multiple government departments [2] - Global initiatives, such as Neuralink's plans for large-scale production and optimized surgical processes, alongside domestic advancements from companies like Shanghai Ladder Medical and Boruikang, indicate a clearer path for domestic technology development [2]

Group 1 - The Hong Kong stock market welcomed three "hard technology" IPOs on January 8, with all three stocks experiencing gains [1] - Among them, Precision Medical showed the most impressive performance, rising over 26% [2] - Precision Medical raised HKD 1.2 billion (approximately USD 154 million) in its IPO, with a share price of HKD 43.24 and a subscription ratio of 1,091.94 times for the public offering [4] Group 2 - Tian Shu Zhi Xin also performed strongly, with a stock increase of nearly 15% [4] - Tian Shu Zhi Xin is recognized as a leading GPU chip and computing system provider in China, being the first to achieve mass production of inference and training general-purpose GPU chips [6] - The company has also utilized advanced 7nm process technology to reach these milestones [6] Group 3 - Zhi Pu experienced a fluctuation with a rise of over 5%, despite previously breaking its initial offering price [8] - The IPO plan for Zhi Pu includes issuing 37.42 million H-shares at a price of HKD 116.20 per share, aiming to raise approximately HKD 4.348 billion, with an expected market capitalization exceeding HKD 51.1 billion post-listing [9] - The public offering portion of Zhi Pu's IPO received approximately 1,164 times oversubscription [9]

Group 1: Core Insights - Traditional industries are the backbone of China's manufacturing sector, accounting for approximately 80% of key indicators such as value added and employment [1] - The transformation of traditional industries towards high-end, intelligent, and green development is essential for building a modern industrial system [1] Group 2: Cost Reduction and Efficiency Improvement - In Zhengzhou, the use of intelligent manufacturing systems has led to a 10% to 15% increase in production efficiency and a 5% to 10% reduction in delivery cycles, with overall costs decreasing by 3% to 5% [2] - Traditional industries are shifting from relying on scale and experience to a data-driven approach that integrates hardware and software ecosystems [2] Group 3: Smart Factory Development - Over 35,000 basic-level and more than 7,000 advanced-level smart factories have been established since the start of the 14th Five-Year Plan, significantly enhancing production efficiency and reducing costs [3] - Continuous investment in new technology and the application of AI and smart technologies are crucial for traditional industries to enhance their high-end and intelligent capabilities [3] Group 4: Green Development Opportunities - The "dual carbon" goals are driving traditional industries to transition from resource dependency to technology value addition, creating new growth opportunities through smart and green technologies [4] - By 2024, the utilization of recycled resources such as waste steel and waste copper is expected to exceed 400 million tons, highlighting the push for industrial decarbonization and green growth [4] Group 5: Energy Transition and Circular Economy - Traditional energy companies are encouraged to explore clean energy development, while steel companies can utilize recycled materials to reduce costs and emissions [5] - The development of carbon trading markets presents opportunities for traditional industries to profit from energy-saving and emission-reduction efforts [5] Group 6: Consumer Market Dynamics - The expanding consumer market is providing new opportunities for traditional industries, emphasizing the need for precise alignment of production with consumer preferences [7] - The demand for higher quality and diverse products is driving traditional industries to innovate and enhance product offerings [8] Group 7: Value Enhancement Challenges - The ultimate goal for traditional industries is to address the challenge of value enhancement through technological innovation and brand building [9] - Improving product quality and brand premium capabilities are essential for driving value enhancement in traditional enterprises [9]

Core Viewpoint - Venezuela has agreed to use its oil sales revenue exclusively for purchasing American-made goods, including agricultural products, pharmaceuticals, medical equipment, and infrastructure improvements for its energy facilities [1] Group 1 - Venezuela's commitment to allocate oil revenue for American goods indicates a potential shift in its economic strategy [1] - The types of goods specified for purchase include essential items such as food, medicine, and energy infrastructure, which could impact both the Venezuelan economy and U.S. exports [1] - There has been no official response from the Venezuelan government regarding this announcement, leaving the details of the agreement unclear [1]

Group 1 - The procurement will include American agricultural products, as well as American-manufactured pharmaceuticals, medical devices, and instruments [1]

Group 1 - The core viewpoint of the article is that Boshi Co., Ltd. (002698) utilizes the equity method for accounting its stake in Harbin Sizerui Intelligent Medical Equipment Co., Ltd., indicating that any profit or loss from Sizerui will impact the company's long-term equity investment and investment income [1] Group 2 - The company has clarified its accounting approach in response to investor inquiries on an interactive platform [1] - The financial performance of Harbin Sizerui will directly influence Boshi's financial statements, particularly in terms of long-term investments and income [1]

Group 1: Company Highlights - Three new stocks are set to be listed in Hong Kong on January 8, with all showing gains in the dark trading session prior to listing [1][2][3] - AI model developer Zhihui (2513.HK) closed at HKD 123.2, up 6.02% from the IPO price of HKD 116.2, indicating a profit of HKD 700 per lot of 100 shares [1] - Zhihui ranks first among independent general model developers in China and second among all general model developers, with a market share of 6.6% according to Frost & Sullivan [1] - Surgical robot company Jingfeng Medical-B (2675.HK) closed at HKD 60.15, a 39.11% increase from the IPO price of HKD 43.24, yielding a profit of HKD 1,691 per lot [2] - Jingfeng Medical focuses on designing, developing, and manufacturing surgical robots, with products in various stages of research and development [2] - General GPU chip and AI computing solution provider Tianshu Zhixin (9903.HK) closed at HKD 198.2, up 37.07% from the IPO price of HKD 144.6, resulting in a profit of HKD 5,360 per lot [2] - Tianshu Zhixin offers a range of general GPU products and AI computing solutions, targeting various industries including cloud computing and AI model development [2] Group 2: Market Performance - Zhihui's trading volume reached 3.5958 million shares, with a total market capitalization of HKD 54.236 billion [1] - Jingfeng Medical's trading volume was 1.7203 million shares, with a total market capitalization of HKD 23.321 billion [3] - Tianshu Zhixin's trading volume was 0.9513 million shares, with a total market capitalization of HKD 50.406 billion [3]